Business
Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy
The partnership underscores Servier’s commitment to developing targeted therapies that address unmet medical needs in oncologyServier will develop and commercialize BDTX-4933, a Phase 1 asset with best-in-class potential targeting both RAS mutations and RAF alterations, in solid tumors, including non-small cell lung cancerBlack Diamond will receive an upfront payment of $70 million and up to $710 million in development and commercial sales milestone payments plus royalties SURESNES, France and C
About this update from Black Diamond Therapeutics, Inc.
[{"type":"image","alt":"Black Diamond Therapeutics, Inc","displaySize":"","headline":null,"caption":"Black Diamond Therapeutics, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":89,"url":"https://media.zenfs.com/en/globenewswire.com/497f244e89de775874fac406d50e11cb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/vwkphi42thFYY0QCBIsk8Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/497f244e89de775874fac406d50e11cb","width":300,"height":89}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"The partnership underscores Servier’s commitment to developing targeted therapies that address unmet medical needs in oncology","length":126,"tagName":"p"}]},{"val":[{"type":"text","content":"Servier will develop and commercialize BDTX-4933, a Phase 1 asset with best-in-class potential targeting both RAS mutations and RAF alterations, in solid tumors, including non-small cell lung cancer","length":198,"tagName":"p"}]},{"val":[{"type":"text","content":"Black Diamond will receive an upfront payment of $70 million and up to $710 million in development and commercial sales milestone payments plus royalties","length":159,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":483,"olType":false},{"type":"text","content":"SURESNES, France and CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Servier, an independent global pharmaceutical group governed by a non-profit foundation, and Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced a strategic worldwide licensing agreement for BDTX-4933, a potential best-in-class targeted therapy for solid tumors. Under this global agreement, Servier will develop and commercialize BDTX-4933, a small molecule designed by Black Diamond Therapeutics to address unmet medical needs in RAF/RAS-mutant solid tumors.","length":681,"tagName":"p"},{"type":"text","content":"“At Servier, we are dedicated to transforming patient care in areas with significant unmet needs. Our partnership to develop BDTX-4933 is an important opportunity in targeted cancer therapies, as we believe we can serve more people by helping the right patients find the right treatment, at the right time,” said...